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Two ﬁ xed-dose artemisinin combinations for drug-resistant 
falciparum and vivax malaria in Papua, Indonesia: an open-
label randomised comparison
A Ratcliﬀ , H Siswantoro, E Kenangalem, R Maristela, R M Wuwung, F Laihad, E P Ebsworth, N M Anstey, E Tjitra, and R N Price
Summary
Background The burden of Plasmodium vivax infections has been underappreciated, especially in southeast Asia 
where chloroquine resistant strains have emerged. Our aim was to compare the safety and eﬃ  cacy of 
dihydroartemisinin-piperaquine with that of artemether-lumefantrine in patients with uncomplicated malaria 
caused by multidrug-resistant P falciparum and P vivax.
Methods 774 patients in southern Papua, Indonesia, with slide-conﬁ rmed malaria were randomly assigned to receive 
either artemether-lumefantrine or dihydroartemisinin-piperaquine and followed up for at least 42 days. The primary 
endpoint was the overall cumulative risk of parasitological failure at day 42 with a modiﬁ ed intention-to-treat analysis. 
This trial is registered with ClinicalTrials.gov, trial number 00157833.
Findings Of the 754 evaluable patients enrolled, 466 had infections with P falciparum, 175 with P vivax, and 113 with a 
mixture of both species. The overall risk of failure at day 42 was 43% (95% CI 38–48) for artemether-lumefantrine and 
19% (14–23) for dihydroartemisinin-piperaquine (hazard ratio=3·0, 95% CI 2·2–4·1, p<0·0001). After correcting for 
reinfections, the risk of recrudescence of P falciparum was 4·4% (2·6–6·2) with no diﬀ erence between regimens. 
Recurrence of vivax occurred in 38% (33–44) of patients given artemether-lumefantrine compared with 10% (6·9–14·0) 
given dihydroartemisinin-piperaquine (p<0·0001). At the end of the study, patients receiving dihydroartemisinin-
piperaquine were 2·0 times (1·2–3·6) less likely to be anaemic and 6·6 times (2·8–16) less likely to carry vivax 
gametocytes than were those given artemether-lumefantrine.
Interpretation Both dihydroartemisinin-piperaquine and artemether-lumefantrine were safe and eﬀ ective for the 
treatment of multidrug-resistant uncomplicated malaria. However, dihydroartemisinin-piperaquine provided greater 
post-treatment prophylaxis than did artemether-lumefantrine, reducing P falciparum reinfections and P vivax 
recurrences, the clinical public-health importance of which should not be ignored.
Introduction
Resistance to antimalarial drugs is emerging throughout 
tropical regions. WHO recommends the use of 
artemisinin combination therapies to improve 
antimalarial eﬀ ectiveness and keep the selection of drug-
resistant parasites to a minimum. Although more than 
60 countries now advocate changing antimalarial policy 
to artemisinin combination therapies, debate still 
continues as to the most suitable combination and how 
these new treatments should be deployed and funded.
Southeast Asia has been a focus for emergence of drug 
resistant strains of Plasmodium falciparum for more than 
40 years, but drug resistance in Plasmodium vivax has 
evolved slower than in P falciparum. The ﬁ rst chloroquine 
resistant isolates of P vivax were reported from Papua, 
Indonesia, and Papua New Guinea,1,2 and cases have also 
been reported from Myanmar, India and South America.3–5 
In a study from southern Papua, the risk of failure within 
28 days was 65% after chloroquine monotherapy for 
P vivax and 48% after chloroquine plus sulfadoxine and 
pyrimethamine for P falciparum.6 These risks are similar to 
those in studies from north Papua.7,8 Virtually no published 
data exist as to how best to treat chloroquine resistant 
P vivax.9,10 Since most patients in endemic countries are 
diagnosed and treated without diﬀ erentiation of the species 
of infection and since the risk of early relapse from the 
hypnozoite liver stages after treatment of P vivax or even 
P falciparum (alone) infections often exceeds 40%,11 it is 
becoming apparent that we need to quantify the burden of 
recurrent P vivax infection and investigate alternative 
treatment strategies.
Artemether-lumefantrine is the only widely available 
coformulated artemisinin combination therapy that is 
produced to international good manufacturing practice 
standards, and has therefore become the preferred choice 
in many endemic countries. The only other widely 
available ﬁ xed-dosed treatment is dihydroartemisinin-
piperaquine. The antimalarial activity of piperaquine has 
been recognised since the 1960s, although its use in 
clinical practice has been restricted mainly to China, 
where piperaquine replaced chloroquine in the national 
malaria control programme in 1978. In the past 5 years 
there has been evidence that dihydroartemisinin-
piperaquine is eﬀ ective against multidrug-resistant 
strains of P falciparum.12–15
In Papua, where drug resistance has emerged to both 
P falciparum and P vivax, we undertook a randomised 
comparative study to establish the safety and eﬃ  cacy of 
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artemether-lumefantrine and dihydroartemisinin-
piperaquine for the treatment of patients with 
uncomplicated malaria, who presented to rural clinics 
with infection with P falciparum, P vivax, or a mixture of 
both species.
Methods
Study site and design
Our study was undertaken in two established rural 
outpatient clinics, 6 km apart and 20 km west of the city of 
Timika, in south Papua, Indonesia. This forested lowland 
area has unstable malaria transmission associated with 
three mosquito vectors: Anopheles koliensis, A farauti, and 
A Punctulatus.16,17 The yearly incidence of malaria in the 
region is 938 per 1000 person-years, with a P falciparum 
and P vivax infection ratio of 57/43. Both species have a 
high rate of chloroquine resistance.6 Ethnic origin of the 
local population is diverse because of economic migration, 
with highland Papuans, lowland Papuans, and non-
Papuans all living in the region. In view of the high 
number of infections in non-immune patients, local 
protocols recommend that all patients with patent 
parasitaemia are given antimalarial therapy. Previous 
studies have reported that the pyrogenic density in this 
region is 1000/µL for P falciparum and 400/µL for 
P vivax.7,9
We did a prospective open-label randomised comparison 
of artemether-lumefantrine (Coartem, Novartis Pharma, 
Basel, Switzerland) with dihydroartemisinin-piperaquine 
(Artekin, Holleykin Pharmaceuticals, Guangzhou, China) 
for the treatment of infections with P falciparum, P vivax, 
or a mixture of both species, in children and adults with 
uncomplicated symptomatic malaria. Our study was 
based on the 2003 WHO in-vivo antimalarial drug 
sensitivity protocol,18 which was modiﬁ ed to include 
mixed infections and any parasitaemia. Patients were 
followed up for 42 days with a standard clinical record 
form for drug eﬀ ectiveness. 
The primary endpoint was the overall cumulative risk 
of any parasitaemia reappearing during the 42-day follow-
up. Previous studies have shown that 95% of true 
recrudescensces after artemisinin combination therapies 
will take place within this time.19 Secondary endpoints 
included the risk of reappearance of P falciparum, P vivax, 
and true recrudescent P falciparum, and the proportion of 
parasitaemic patients on days 1, 2, and 3, post-treatment 
gametocyte carriage, and haematological recovery. When 
parasite count, gametocyte carriage, or haemo globin were 
missing, numbers were restricted to patients with 
acceptable data presenting on speciﬁ c days. Although this 
study was open labelled, the ﬁ nal endpoints were 
determined by microscopic conﬁ rmation and PCR 
analysis, which were done blind to treatment allocation.
The study was approved by the Ethics committee of the 
National Institute of Health Research and Development, 
Indonesian Ministry of Health (Jakarta, Indonesia), the 
Ethics committee of Menzies School of Health Research 
(Darwin, Australia), and the Oxford Tropical Research 
Ethics Committee (Oxford, UK). Written informed 
consent was obtained from adult patients and parents of 
enrolled children. The trial was registered with 
clinicaltrials.gov, number NCT 00157833. 
Patients
Patients with slide-conﬁ rmed malaria (P falciparum, 
P vivax, or mixed infections) and fever or a history of 
fever during the preceding 48 h, who presented to the 
outpatient clinic, were eligible for enrolment. Pregnant 
or lactating women and children under 10 kg were 
excluded, as were patients with WHO danger signs or 
signs of severity,20 a parasitaemia greater than 4%, or 
concomitant disease requiring hospital admission. To 
focus resources and ensure adequate follow-up of the 
patients enrolled, we restricted recruitment to a 
maximum of ﬁ ve patients per day from each clinic.
Procedures
After enrolment, patients were randomly assigned to 
receive either artemether-lumefantrine or dihydro-
artemisinin-piperaquine. A randomisation list was 
generated in blocks of 20 patients by an independent 
statistician, with each treatment allocation concealed in 
an opaque sealed envelope that was opened once the 
patient had been enrolled. A standard data sheet was 
completed to record demographic information, details of 
symptoms and their duration, and previous antimalarial 
medication. Clinical examination ﬁ ndings were 
documented, including the axillary temperature that was 
measured with a digital thermometer. Venous blood was 
taken for blood ﬁ lm, haematocrit (packed cell volume), 
and white cell count. Parasite counts were done on 
Giemsa-stained thick ﬁ lms as the number of parasites 
per 200 white blood cells, and peripheral parasitaemia 
was calculated on the assumption of a white cell count of 
7300/µL. All slides were read by a certiﬁ ed microscopist 
with at least 10 years experience, who was blinded to 
treatment allocation. A thick smear was regarded as 
negative on initial review if no parasites were seen in 
100 high power ﬁ elds. A thin smear was also examined to 
conﬁ rm parasite species and used for quantiﬁ cation if 
parasitaemia was greater than 200 per 200 white blood 
cells. To cross check, 200 high power ﬁ elds were examined 
before slides were regarded as negative. All slides were 
cross checked by a second experienced microscopist. In 
9% of cases, in which readings were discordant with the 
ﬁ rst reading, slides were reread by a third microscopist 
and a consensus reached. 
Patients were examined every day thereafter until they 
became afebrile and parasite free. A blood smear was 
taken and a symptom questionnaire completed at every 
visit. Patients were then seen every week for 6 weeks. At 
each clinic appointment a full physical examination was 
done, the symptom questionnaire completed, and blood 
taken to check for parasite count and haemoglobin 
Articles
www.thelancet.com    Vol 369   March 3, 2007 759
concentration with a battery operated portable photometer 
(HemoCue Hb201+, Angelholm, Sweden). Blood spots 
on ﬁ lter paper (Whatman chromatography paper 
[Whatman BFC 180, Maidstone, UK]) were also obtained 
at enrolment and day of failure.
Artemether-lumefantrine was dispensed according to 
patients’ weight. Patients weighing 10–15 kg received one 
tablet per dose, those weighing 15–25 kg received two, 
those of 25–35 kg received three, and those greater than 
35 kg received four. In total, six doses were given over 
3 days: on admission and at 8, 24, 36, 48, and 60 h. The 
morning dose was supervised and the patient then given 
the evening dose to take themselves.
Dihydroartemisinin-piperaquine was given as a weight 
per dose regimen of 2·25 mg/kg and 18 mg/kg per dose 
of dihydroartemisinin and piperaquine, respectively, 
rounded up to the nearest half tablet. All doses were 
supervised and given on admission, after 24 h, and 
at 48 h.
Since the bioavailability of both lumefantrine and 
piperaquine is increased if taken with a fatty meal,21,22 
patients were instructed to take every dose with a biscuit 
or milk. When drug administration was observed and 
vomiting happened within 60 minutes, the full dose was 
given again. If the axillary temperature was greater than 
38°C, paracetamol was given. Patients failing therapy 
with recurrence of P falciparum were retreated with 
quinine (10 mg of salt per kg of body weight, given orally 
three times a day for 7 days) with additional doxycycline 
(100 mg twice a day for 7 days) if the patient was older 
than 8 years. Patients with reappearance of P vivax were 
oﬀ ered a 3-day course of supervised amodiaquine 
(Flavoquine, Aventis, Paris, France. 153 mg base per 
tablet, 30 mg/kg over 3 days) or, if they refused to return 
for supervised therapy, quinine with or without 
doxycycline. Indonesian protocols recommend the use of 
primaquine (0·3 mg of base/kg of bodyweight for 14 days) 
for patients with P vivax infection, but to decrease 
potential drug interaction, administration was delayed 
until day 28 of the study. 
Statistical analysis
Statistical analysis was done accordingly to an a-priori 
analytical plan, in which estimates of eﬃ  cacy were 
derived from all patients who did not violate any of the 
inclusion or exclusion criteria (ie, modiﬁ ed intention-
to-treat). 
In a pilot study,6 60% of patients presenting to the 
clinics with uncomplicated malaria had P falciparum, 
25% had P vivax, and 15% had mixed infections. On the 
assumption that 96% of patients are cured after 
artemether-lumefantrine or dihydro arte misinin-piper-
aquine is given fully supervised, a total sample size of 
750 patients would record the risk of failure for each 
regimen within 3% that of the true risk (allowing for 
30% loss during follow-up). Furthermore, the study had 
80% power and 95% conﬁ dence to detect a 10% diﬀ erence 
in the risk of failure that might have resulted from a 
policy in which drug administration was supervised only 
once daily (a practical constraint of widespread 
deployment). 
Data were double entered and validated with EpiData 
software (version 3.02) and analysed with SPSS for 
Windows (version 14). The Mann-Whitney U test or 
Kruskal-Wallis method were used for non-parametric 
comparisons, and t test or one-way analysis of variance 
for parametric comparisons. For categorical variables, 
percentages and 95% CIs were calculated by Wilson’s 
method. Proportions were examined by χ² test with Yates’ 
correction or by Fisher’s exact test.
The cumulative risk of failure was assessed by survival 
analysis with the Kaplan Meier method on a modiﬁ ed 
intention to treat basis. Anyone lost during follow-up or, 
in the case of secondary endpoints, presenting with a 
 481 did not meet eligibility criteria
 236 refused or unable to follow-up
 1982 unable to enrol* 
 8 protocol violations
 6 microscopy errors
 1 severe repiratory distress
 1 lactating mother
 12 protocol violations
 10 microscopy errors
 1 severe anaemia
 1 other comorbidity
 6 early treatment failures†
 1 seizure
 4 recurrent vomiting
 1 adverse events—rash
 6 early treatment faliures†
 1 clinical deterioration
 3 recurrent vomiting
 2 adverse events—urticaria
 82 incomplete follow-up
 3 other antimalarials during 
  follow-up
 4 other disease during follow-up
 75 lost to follow-up (8 incomplete
  course of medication)
 105 incomplete follow-up
    4 other antimalarials during 
  follow-up
 2 other disease during follow-up
 99 lost to follow-up (14 incomplete 
  course of medication)
 12 P falciparum
 20 mixed infections
 87 P vivax
 2 P ovale
 121 late failures
 22 P falciparum
 5 mixed infections
 15 P vivax
 42 late failures
 379 evaluable population
 232 P falciparum
 57 mixed infections
 90 P vivax
3473 patients presenting to clinics
 774 enrolled and randomised
 387 dihydroartemisinin-piperaquine 387 artemether-lumefantrine
 226 adequate clinical response 166 adequate clinical response
 375 evaluable population
 234 P falciparum
 56 mixed infections
 85 P vivax
Figure 1: Trial Proﬁ le
*Maximum of 5 patients enrolled per clinic each day. †WHO criteria or recurrent vomiting or adverse event 
warranting rescue therapy.
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diﬀ erent outcome, were censored on their last day of 
follow-up and regarded as not being treatment failures. 
Patients failing to complete a 42-day follow-up for any 
other reason were regarded as treatment failures. Those 
with recurrent vomiting or adverse drug eﬀ ects, who 
required early cessation of treatment and rescue therapy, 
were regarded as early therapeutic failures. Groups were 
compared by use of the Mantel-Haenszel log rank test 
and the hazard ratio (HR) was presented. Furthermore, 
treatment outcomes were compared and HR calculated 
after stratiﬁ cation for the initial infecting parasite 
species with Cox proportional hazards model.
In patients with P falciparum (alone or mixed infection) 
in both initial and recurrent parasitaemia, polymorphisms 
within the genes that encode MSP-1 (merozoite speciﬁ c 
protein), MSP-2, and GLURP (glutamate-rich protein) 
were used to record reinfections and recrudescent in-
fections, with PCR methods described previously.23 In total, 
43 patients had paired infections with P falciparum initially 
(alone or mixed) and at the time of recurrence. Of the 70% 
(30/43) of these paired samples that could be interpreted, 
87% (26/30) were reinfections. Hence, in the 30% (13/43) 
of cases in whom the PCR result was unavailable or 
uninterpretable the reappearance of P falciparum was 
regarded, on balance, as reinfection. When the risk of 
recrudescent P falciparum was calculated, all early treat-
ment failures and true recrudescences were regarded as 
failures, but P falciparum reinfections and recurrences of 
P vivax were censored as non-failures in survival analysis.
Gametocyte carriage was assessed by calculation of 
person gametocyte week rates as a measure of transmission 
potential. These rates were deﬁ ned as the number of 
weeks in which blood slides were positive for gametocytes 
during 6-week follow-up, divided by the total number of 
weeks followed up, and were expressed per 1000 person-
weeks.24 Adverse events reported were generally associated 
with acute malaria, and hence comparison between 
treatment groups was made in patients without the 
symptom on admission but who developed the complaint 
after starting antimalarial treatment.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Between July, 2004, and June, 2005, 3473 patients with 
uncomplicated malaria were treated at the recruitment 
clinics. For the 2992 (86%) patients meeting the eligibility 
Artemether-lumefantrine 
(n=375)
Dihydroartemisinin-
piperaquine (n=379)
Species at enrolment
P falciparum (%) 234 (62%) 232 (61%)
   Geometric mean parasitaemia per µL (95%CI) 3790 (2995–4796) 3386 (2674–4289)
   Parasitaemia >1000/µL 177 (76%) 180 (78%)
P vivax 85 (23%) 90 (24%)
   Geometric mean parasitaemia per µL (95%CI) 2143 (1532–2997) 2448 (1729–3465)
   Parasitaemia >400/µL 71 (84%) 74 (82%)
Mixed Infections (%) 56 (15%) 57 (15%)
   Geometric mean parasitaemia per µL (95%CI) 4459 (2779–7158) 4304 (2887–6416)
   Parasitaemia >400/µL 50 (89%) 54 (95%)
Male patients 231 (60%) 244 (58%)
Weight (kg) (median, range) 46 (10–104) 48 (10–83)
Age (years) (median, range) 18 (1–60) 17 (1–60)
<5 years  48 (13%) 48 (13%)
5-14 years  109 (29%) 118 (31%)
>14 years  218 (58%) 213 (56%)
Temperature >37·5ºC  128 (34%) 118 (31%)
History of malaria in previous month 64 (17%) 74 (20%)
Haemoglobin (g/L)  (mean, SD) 98 (25) 98 (24)
Splenomegaly 261 (70%) 248 (65%)
Data are number (%), unless otherwise indicated. 
Table 1: Patient characteristics at baseline
Artemether-lumefantrine Dihydroartemisinin-piperaquine Hazard ratio p value
Parasitological failure with any species 
Initial infection with any species* 375 43% (38–48) 379 19% (14-23) 3·0 (2·2–4·1)† <0·0001
Parasitological failure with P falciparum
Initial infection with any species‡ 375 15% (11–20) 379 13% (9–17) 1·3 (0·9–2·1)† 0·186
True recrudescence of P falciparum‡§ 290 4·7% (2·0–7·4) 289 4·1% (CI 1·6–6·6) 1·2 (0·5–2·9) 0·604
Parasitological failure with P vivax
Initial infection with any species‡ 375 38% (33–44) 379 10% (6·9–14·0) 4·8 (3·2–7·2)† <0·0001
Initial infection with P vivax (pure or mixed) 141 57% (48–66) 147 14% (7·3–20·0) 5·5 (3·2–9·5) <0·0001
Eﬃ  cacy rates were calculated from the modiﬁ ed intent-to-treat population, in which patients failing to complete a 42-day follow-up, other than those lost to follow-up, were 
regarded as treatment failures (seven in artemether-lumefantrine group and six in dihydroartemisinin-piperaquine group); hence these are conservative estimates for 
comparative analysis. *Primary endpoint. †The hazard ratio was calculated with a Cox proportional hazards model after stratifying for the initial species of infection. 
‡Secondary endpoint. §After correcting by PCR genotyping, patients with P falciparum (alone or mixed) initially and at failure. Data are n, % (95%CIs). 
Table 2: Cumulative risk of failure at day 42
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criteria, age and sex distribution did not diﬀ er between 
the 774 (26%) patients enrolled and the whole clinic 
workload. There were 20 protocol violations all of which 
were identiﬁ ed within 24 h, oﬀ ered alternative treatment, 
and excluded from further analysis (ﬁ gure 1). Of the 
remaining 754 patients, 466 (62%) had only P falciparum 
infection, 175 (23%) had P vivax infection, and 113 (15%) 
had both species present. Table 1 shows the baseline 
characteristics. Overall, follow-up to day 42 or day of 
failure was achieved in 78% (293/375) of patients given 
artemether-lumefantrine and 72% (274/379) given 
dihydroartemisinin-piperaquine (p=0·076). 
Seven (1%) of the 754 patients correctly enrolled were 
unable to tolerate their drug because of recurrent 
vomiting (ﬁ gure 1). Two patients developed urticaria on 
day 1, and one developed a non-speciﬁ c erythematous 
rash on day 2. These patients were regarded as treatment 
failures and were given quinine either orally or 
intravenously. They all had unremarkable recoveries.
Early clinical deterioration that needed hospital 
treatment was seen in two patients. A 3-year-old boy 
with only P falciparum infection developed respiratory 
distress, prostration, and profuse diarrhoea 24 h after 
his ﬁ rst dose of artemether-lumefantrine. He was 
admitted, was given intravenous ﬂ uids and quinine, and 
made a full recovery. A 5-year-old girl with mixed 
parasitaemia and high fever vomited after her ﬁ rst dose 
of dihyrdoartemisinin-piperaquine and 30 minutes later 
developed a complex partial seizure. She was transferred 
to hospital where she was given intravenous quinine 
and made a full recovery.
73% (254/350) of the remaining patients given 
dihydroartemisinin-piperaquine had cleared their 
parasites within 24 h, compared with 57% (192/339) of 
those who received artemether-lumefantrine (p<0·0001). 
By day 2, 97% (690/712) of patients were parasite free and 
99% (662/671) were afebrile, with no diﬀ erence between 
treatment groups.
A total of 163 patients had recurrent parasitaemia during 
follow-up, of which 34 infections were attributable to 
P falciparum alone, 102 to P vivax alone, two to P ovale 
alone, and 25 contained both species. Overall 53% (85/161) 
of recurrences were symptomatic, 12% (19/159) had 
documented fever, and 33% (43/131) were anaemic 
(haemoglobin <100 g/L). These pro portions did not diﬀ er 
between treatment groups or infecting species.
The cumulative risk of any parasitological failure was 
greater after artemether-lumefantrine than after 
dihydroartemisinin-piperaquine (HR 3·0, 95% CI 
2·2–4·1, p<0·0001, table 2). Reappearance of P falciparum 
(alone or mixed) was much the same in the two groups 
(32 patients after artemether-lumefantrine and 27 after 
dihydroartemisinin-piperaquine, table 2). Although by 
day 42 reappearance of P falciparum did not diﬀ er 
between treatment groups, the time to reappearance 
was longer in patients receiving dihydroartemisinin-
piperaquine (median 38 days, range 21–45) than in those 
receiving artemether-lumefantrine (34 days, 19–43), 
p=0·018 (ﬁ gure 2). The risk of recurrent P falciparum 
infections was not dependent on the species of the 
initial infection. After PCR correction, the risk of true 
recrudescent P falciparum during follow-up was less 
than 5% in both treatment groups (table 2).
Recurrence of P vivax (alone or mixed) was recorded 
in 127 patients. By day 42, the cumulative risk of P vivax 
was greater in patients given artemether-lumefantrine 
than in those given dihydroartemisinin-piperaquine 
(38% vs 10%, table 2, ﬁ gure 2). The cumulative risk of 
P vivax recurrence took place in 36% (95%CI 28–44) of 
patients initially infected with P vivax, 17% (13–21) of 
those with P falciparum, and 36% (26–46) of those with 
mixed infections (p<0·0001). After stratiﬁ cation by the 
species at presentation, the hazard ratio for P vivax 
reappearance associated with artemether-lumefantrine 
was 4·8 (95%CI 3·2–7·2), p<0·0001 (table 2).
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Figure 2: Cumulative risk of patients failing with P falciparum (upper) and P vivax (lower) parasitaemia (alone 
or mixed)
Overall diﬀ erence between treatment groups at day 42, after stratifying for the initial species of infection, for 
P falciparum, p=0·186; for P vivax, p<0·0001. 
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On admission, P falciparum gametocytes were present 
in 21% (122/574) of patients with P falciparum alone or 
mixed infections. In patients without gametocytes on 
presentation, the falciparum gametocyte carriage during 
follow-up was 5·7 per 1000 person-weeks, with no 
diﬀ erence between treatment groups.
P vivax gametocytes on admission were present in 
56% (160/284) of patients with P vivax alone or mixed 
infections. After day 7, P vivax gametocytaemia was 
always associated with recurrence of the organism’s 
asexual stages, with carriage occurring at a rate of 
3·7 per 1000 patient-weeks after dihydroartemisinin-
piperaquine compared with 24·6 after artemether-
lumefantrine (rate ratio [RR]=6·6, 95%CI 2·8–16·0, 
p=0·0002) (ﬁ gure 3).
Baseline haemoglobin concentrations were assessed 
in 99% (750/754) of patients, 387 (52%) of whom had 
anaemia (haemoglobin <100 g/L). Haemoglobin 
concentrations were available in 42% (1403/3326) of the 
subsequent reviews of patients, with no diﬀ erence 
between treatment groups. Although the mean 
haemoglobin concentrations initially rose after 
treatment (ﬁ gure 4), by the end of the study the mean 
haemoglobin in patients with a recurrent parasitaemia 
was 10·2 g/L (95% CI 4·4–16·0) lower than those 
successfully treated (p<0·0001). The corresponding risk 
of anaemia was 33% (45/135) in patients failing therapy 
compared with 19% (21/111) in those successfully 
treated (RR=1·8, 95% CI 1·1–2·8, p=0·02). By day 42, 
35% (24/68) of patients given artemether-lumefantrine 
were anaemic, compared with 17% (15/86) of those who 
received dihyrdoartemisinin-piperaquine (relative risk 
2·0, 1·2–3·6, p=0·019).
Early vomiting within the ﬁ rst hour of drug 
administration was recorded in 2·7% (ten of 375) of 
patients given artemether-lumefantrine and 2·9% (11/379) 
of patients given dihydroartemisinin-piperaquine. 11% 
(11/96) of children less than 5 years of age vomited the 
drug, compared with 3% (seven of 227) in older children, 
and 1% (three of 431) in adults (p<0·0001).
Adverse events were assessed in patients without the 
symptom at enrolment (ﬁ gure 5). The only diﬀ erence 
between the two treatment groups was a two-fold (95% 
CI 1·3–3·3) increased risk of diarrhoea on days 1 and 2, 
which arose in more patients receiving dihydro-
artemisinin-piperaquine than in those given artemether-
lumefantrine. By day 7, the risk of diarrhoea was 5% in 
both treatment groups. Although 35% (12/34) of patients 
developed a headache on days 1 and 2 after 
dihydroartemisinin-piperaquine (compared with 23% 
[nine of 40] of patients given artemether-lumefantrine), 
the diﬀ erence was not signiﬁ cant since headache was a 
common symptom at presentation.
The three patients who developed urticaria (two on 
day 1 and one on day 2 [after his ﬁ nal dose and not 
included as treatment failure]) were treated with 
antihistamines and all made a complete recovery. A 
3-year-old child who developed an erythematous rash on 
day 1 was treated with antihistamines and the rash had 
resolved by day 4. A 32-year-old man died suddenly and 
unexpectedly 60 days after treatment with artemether-
lumefantrine. He had been assessed on day 28 and was 
reported as being well—analysis of his blood on day 
28 revealed no haematological or biochemical abnor-
malities. No further details were available.
Of the 163 patients with recurrent parasitaemia, 
139 (85%) agreed to be retreated and followed up for a 
further 28 days. Of the 48 patients representing with 
P falciparum (alone or mixed infections), who were given 
an unsupervised course of quinine with or without 
doxycycline, the risk of failure at day 28 rose to 83% 
(95% CI 70–96). Of the 91 patients with a recurrence of 
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P vivax alone, 26 patients were retreated with an 
unsupervised course of quinine plus primaquine with or 
without doxycycline, with a subsequent risk of failure of 
57% (36–79). The remaining 65 patients with P vivax were 
retreated with a supervised course of amodiaquine plus 
primaquine. Two patients had recurrent vomiting, four 
failed to complete therapy, and 18 had recurrent 
parasitaemia by day 28 (one with P falciparum, nine with 
P vivax, and eight with mixed infections). By day 28, the 
cumulative risk of recurrence with P vivax was 
26% (12–40).
Discussion
Our pragmatic study design is novel, enrolling and 
randomising patients infected with either species and 
then quantifying the subsequent risk of recurrence and 
associated morbidity. We have assessed the eﬃ  cacy of 
two widely available ﬁ xed-dose artemisinin combinations 
for patients with drug-resistant P falciparum and P vivax. 
Both artemether-lumefantrine and dihydroartemisinin-
piperaquine were well tolerated and associated with a 
rapid clinical response. Although the initial parasite 
clearance was signiﬁ cantly faster after dihydro-
artemisinin-piperaquine, almost all patients in both 
groups were parasite free and afebrile within 48 h. 
However, by the end of follow-up, the cumulative risk of 
parasitological failure was signiﬁ cantly higher after 
artemether-lumefantrine than after dihydroartemisinin-
piperaquine. Over half these recurrent parasitaemias 
were associated with clinical symptoms and a third with 
anaemia, with P falciparum and P vivax malaria associated 
with equal morbidity. 
The risk of true recrudescence with P falciparum was 
less than 5% in both treatment groups, and most 
P falciparum recurrences were caused by reinfections. 
These ﬁ ndings are in keeping with previous eﬃ  cacy 
studies of artemether-lumefantrine25,26 and dihydro-
artemisinin-piperaquine12–15 and suggest that most 
patients, even those who were only partly supervised, 
completed a full course of treatment. 
Overall, most recurrent infections were attributable to 
P vivax, which could have arisen from recrudescence 
from the same isolate, reinfection with a new isolate, or 
relapse from hypnozoite stages.27 Although there are as 
yet no reliable genetic methods for discerning between 
these possibilities, the discrepancy between the 
cumulative risk of failure probably arose as a result of the 
diﬀ erence between the terminal elimination half-life of 
lumefantrine (around 4 days)21 and that of piperaquine 
(28–35 days).28,29 Artemisinin combinations achieve their 
antimalarial eﬀ ect through an initial rapid reduction in 
parasite biomass attributable to the short-term but potent 
artemisinin derivative, with the subsequent removal of 
the remaining parasites by the intrinsically less active but 
more slowly eliminated lumefantrine or piperaquine. 
After eradication of the asexual stages of the parasite 
from peripheral blood, patients who remain in an 
endemic area are at risk of reinfection or, in P vivax 
endemic areas, from relapses from the liver stage 
hypnozoites. Slowly eliminated antimalarial drugs will 
exert a greater post-treatment prophylactic eﬀ ect than 
those that are more rapidly eliminated, and this enhanced 
eﬀ ect is seen in both the rates of reinfection and relapse. 
The greater the risk of P vivax relapse or reinfection with 
either species, the more apparent this prophylactic eﬀ ect 
will probably become.
In our study, the ﬁ rst P vivax recurrence took place 
17 days after artemether-lumefantrine was given. By 
contrast, the ﬁ rst recurrence after dihydroartemisinin-
piperaquine did not take place until day 29. The delay in 
P falciparum reinfection was also marked, but smaller than 
for P vivax . We were unable to follow up patients for any 
longer than 6 weeks, but if we had done so the survival 
curves would probably have merged over time as the 
plasma concentrations of piperaquine fell. However, the 
delay in relapse and reinfections conferred by dihydro-
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artemisinin-piperaquine gave patients a lengthened period 
without symptomatic malaria, allowing for an increased 
time for haematological recovery, which in turn halved the 
risk of anaemia. The reduction in the recurrence of P vivax 
infections also substantially reduced the transmission 
potential to the mosquito vector. Although the public-
health implications of these results need to be conﬁ rmed 
by longer follow-up and with repeated exposure, our 
ﬁ ndings suggest that further beneﬁ ts will accrue with 
repeated treatments, and that the beneﬁ t will be more 
apparent in patients at greatest risk of infection.
The major concern with deployment of antimalarial 
drugs with long half-life and combinations with 
pharmacokinetic mismatching is that there will be an 
increased risk of selecting drug-resistant isolates.30 Indeed, 
the long subtherapeutic tail of the antifolate sulfadoxine-
pyrimethamine has been directly implicated in the rapid 
spread of resistance to this agent throughout Asia and 
Africa.31 The emergence and spread of resistant parasites 
is determined by two major components: selection de 
novo and selective transmission. Emergence of resistant 
parasites has been argued to be a function of biomass and 
therefore will probably take place in the initial infection 
rather than the reinfecting strains.32 In vivo, the rapid 
reduction of an infecting biomass with an artemisinin 
derivative reduces the number of asexual parasites exposed 
to the second drug, which thus reduces the chances of a 
resistant mutant emerging during treatment.32
If dihydroartemisinin-piperaquine is deployed in an 
area before the emergence of piperaquine resistance, and 
if the artemisinin component can substantially delay the 
emergence of de-novo resistance, then the tangible 
beneﬁ ts accrued by the longacting combination favour 
dihydroartemisinin-piperaquine. Once resistance strains 
emerge in an area, selective transmission in the long 
subtherapeutic tail of this drug is likely to increase the 
spread of resistance and herald the demise of the regimen. 
Careful monitoring of in-vivo and in-vitro antimalarial 
eﬀ ectiveness should therefore remain a priority.
Neither artemether-lumefantrine nor dihydro arte-
misinin-piperaquine aﬀ ects the hypnozoite stages of 
P vivax. Early administration of primaquine, the only 
registered antimalarial agent with activity against 
hypnozoites, could possibly have prevented the high rates 
of relapse due to P vivax that we recorded. However, 
radical cure of P vivax in this area needs high doses of 
primaquine daily, over 14 days,33,34 and in practice such 
long courses of unsupervised therapy are rarely adhered 
to. Hence, although the post-treatment prophylaxis 
aﬀ orded by dihydroartemisinin-piperaquine will not 
prevent subsequent relapses, this drug will provide the 
only practical means available for delaying these relapses 
in such areas. Alternative strategies to deal with the 
hypnozoite stages are needed as a research priority, but 
as yet are not forthcoming.
In conclusion, artemether-lumefantrine and dihydro-
artemisinin-piperaquine proved well tolerated, safe, and 
eﬀ ective treatments for drug-resistant P falciparum. In 
Papua, Indonesia, alternative treatment strategies are 
scarce, but the simple 3-day regimen of dihydro-
artemisinin-piperaquine, its low price, fast clinical 
response, and post-treatment prophylactic eﬀ ect oﬀ er 
substantial beneﬁ ts over artemether-lumefantrine, the 
only other available ﬁ xed-dosed artemisinin combination. 
Although priority should be given to keep the risk of 
recrudescence to a minimum, the clinical and public 
health relevance of reinfections and relapses should not 
be ignored. 
Contributors
Alison Ratcliﬀ , Hadjar Siswantoro, Enny Kenangalem, Maxi Wuwung, 
and Rilia Maristela all participated in undertaking the clinical studies. 
The trial was coordinated and supervised by Emiliana Tjitra, 
Peter Ebsworth, Nick Anstey, and Ric Price. Ferdinand Laihad 
supervised the research programme. All authors participated in the 
design, analysis, interpretation, and writing up of the research work.
Conﬂ ict of interest statement 
RP has received reimbursement of travel expenses to attend meetings by 
Novartis, who manufacturer Coartem, and is on a data safety monitoring 
committee for Sygma Tau, who manufacture dihydroartemisinin-
piperaquine.
Acknowledgments
We thank Lembaga Pengembangan Masyarakat Amungme Kamoro and 
the staﬀ  of PT Freeport Indonesia Public Health & Malaria Control 
Department and International SOS for support and technical assistance; 
Maurits Okoseray, Rosmini, Buhari, Alan Brockman, Kim Piera, and 
Ferryanto Chalfein for their support and technical assistance; Morrison 
Bethea and executive staﬀ  of PT Freeport Indonesia for their support; 
Pascal Ringwald (WHO) for kindly providing the amodiaquine and 
artemether-lumefantrine tablets; and Craig Boutlis for comments on the 
manuscript. The members of the data safety monitoring committee 
were: Allen Cheng, Liliana Kurniawan, Julie Simpson, and Bob Taylor. 
The funding for this study was provided by the Wellcome Trust (UK; 
ICRG GR071614MA) and National Health and Medical Research Council 
(Australia; ICRG ID 283321). NA is supported by an NHMRC 
Practitioner Fellowship. RP is funded by a Wellcome Trust Career 
Development Award, aﬃ  liated to the Wellcome Trust—Mahidol 
University—Oxford Tropical Medicine Research Programme (074637). 
References
1  Rieckmann KH, Davis DR, Hutton DC. Plasmodium vivax 
resistance to chloroquine? Lancet 1989; 334: 1183–84.
2  Baird JK, Basri H, Purnomo, et al. Resistance to chloroquine by 
Plasmodium vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg 1991; 
44: 547–52.
3  Dua VK, Kar PK, Sharma VP. Chloroquine resistant Plasmodium 
vivax malaria in India. Trop Med Int Health 1996; 1: 816–19.
4  Soto J, Toledo J, Gutierrez P, et al. Plasmodium vivax clinically 
resistant to chloroquine in Colombia. Am J Trop Med Hyg 2001; 65: 
90–93.
5  Myat Phone K, Myint O, Myint L, Thaw Z, Kyin Hla A, Nwe Nwe Y. 
Emergence of chloroquine-resistant Plasmodium vivax in Myanmar 
(Burma). Trans R Soc Trop Med Hyg 1993; 87: 687.
6  Ratcliﬀ  A, Siswantoro H, Kenangalem E, et al. Therapeutic response 
of multidrug-resistant Plasmodium falciparum and P vivax to 
chloroquine and sulfadoxine-pyrimethamine in southern Papua, 
Indonesia. Trans R Soc Trop Med Hyg 2007; 101: 351–59.
7 Tjitra E, Suprianto S, Anstey NM. Higher gametocyte prevalence 
following failure of treatment of Plasmodium falciparum malaria 
with sulfadoxine-pyrimethamine and the combination of 
chloroquine plus sulfadoxine-pyrimethamine: implications for 
progression of anti-folate resistance. Trans R Soc Trop Med Hyg 
2002; 96: 434–37.
8  Sumawinata IW, Bernadeta, Leksana B, et al. Very high risk of 
therapeutic failure with chloroquine for uncomplicated Plasmodium 
falciparum and P vivax malaria in Indonesian Papua. 
Am J Trop Med Hyg 2003; 68: 416–20.
Articles
www.thelancet.com    Vol 369   March 3, 2007 765
9 Tjitra E, Baker J, Suprianto S, Cheng Q, Anstey NM. Therapeutic 
eﬃ  cacies of artesunate-sulfadoxine-pyrimethamine and 
chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot 
studies: relationship to Plasmodium vivax dhfr mutations. 
Antimicrob Agents Chemother 2002; 46: 3947–53.
10 Maguire JD, Krisin, Marwoto H, Richie TL, Fryauﬀ  DJ, Baird JK. 
Meﬂ oquine is highly eﬃ  cacious against chloroquine-resistant 
Plasmodium vivax malaria and Plasmodium falciparum malaria in 
Papua, Indonesia. Clin Infect Dis 2006; 42: 1067–72.
11 Baird JK, Leksana B, Masbar S, et al. Diagnosis of resistance to 
chloroquine by Plasmodium vivax: timing of recurrence and whole 
blood chloroquine levels. Am J Trop Med Hyg 1997; 56: 621–26.
12  Tran TH, Dolecek C, Pham PM, et al. Dihydroartemisinin-
piperaquine against multidrug-resistant Plasmodium falciparum 
malaria in Vietnam: randomised clinical trial. Lancet 2004; 363: 
18–22.
13  Ashley EA, Krudsood S, Phaiphun L, et al. Randomized, controlled 
dose-optimization studies of dihydroartemisinin-piperaquine for 
the treatment of uncomplicated multidrug-resistant falciparum 
malaria in Thailand. J Infect Dis 2004; 190: 1773–82.
14  Denis MB, Davis TM, Hewitt S, et al. Eﬃ  cacy and safety of 
dihydroartemisinin-piperaquine (Artekin) in Cambodian children 
and adults with uncomplicated falciparum malaria. Clin Infect Dis 
2002; 35: 1469–76.
15  Smithuis F, Kyaw MK, Phe O, et al. Eﬃ  cacy and eﬀ ectiveness of 
dihydroartemisinin-piperaquine versus artesunate-meﬂ oquine in 
falciparum malaria: an open-label randomised comparison. Lancet 
2006; 367: 2075–85.
16  Lee VH, Atmosoedjono S, Aep S, Swaine CD. Vector studies and 
epidemiology of malaria in Irian Jaya, Indonesia. 
Southeast Asian J Trop Med Public Health 1980; 11: 341–47.
17  Pribadi W, Sutanto I, Atmosoedjono S, Rasidi R, Surya LK, 
Susanto L. Malaria situation in several villages around Timika, 
south central Irian Jaya, Indonesia. 
Southeast Asian J Trop Med Public Health 1998; 29: 228–35.
18 WHO. Assessment and monitoring of antimalarial drug eﬃ  cacy for 
the treatment of uncomplicated falciparum malaria. Document No. 
WHO/HTM/RBM2003.50. Geneva 2003; World Health 
Organisation (2003).
19 Stepniewska K, Taylor WR, Mayxay M, et al. In vivo assessment of 
drug eﬃ  cacy against Plasmodium falciparum malaria: duration of 
follow-up. Antimicrob Agents Chemother 2004; 48: 4271–80.
20  WHO. Severe falciparum malaria. World Health Organization, 
Communicable Diseases Cluster. Trans R Soc Trop Med Hyg 2000; 
94 (suppl 1): S1–90.
21  Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ. 
Pharmacokinetics and pharmacodynamics of lumefantrine 
(benﬂ umetol) in acute falciparum malaria. 
Antimicrob Agents Chemother 2000; 44: 697–704.
22  Sim IK, Davis TM, Ilett KF. Eﬀ ects of a high-fat meal on the relative 
oral bioavailability of piperaquine. Antimicrob Agents Chemother 
2005; 49: 2407–11.
23 Brockman A, Paul RE, Anderson TJ, et al. Application of genetic 
markers to the identiﬁ cation of recrudescent Plasmodium falciparum 
infections on the northwestern border of Thailand. 
Am J Trop Med Hyg 1999; 60: 14–21.
24 Price RN, Nosten F, Luxemburger C, et al. Eﬀ ects of artemisinin 
derivatives on malaria transmissibility. Lancet 1996; 347: 1654–58.
25  Piola P, Fogg C, Bajunirwe F, et al. Supervised versus unsupervised 
intake of six-dose artemether-lumefantrine for treatment of acute, 
uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: 
a randomised trial. Lancet 2005; 365: 1467–73.
26  van Vugt M, Looareesuwan S, Wilairatana P, et al. Artemether-
lumefantrine for the treatment of multidrug-resistant falciparum 
malaria. Trans R Soc Trop Med Hyg 2000; 94: 545–48.
27  White NJ. The assessment of antimalarial drug eﬃ  cacy. 
Trends Parasitol 2002; 18: 458–64.
28  Hung TY, Davis TM, Ilett KF, et al. Population pharmacokinetics of 
piperaquine in adults and children with uncomplicated falciparum 
or vivax malaria. Br J Clin Pharmacol 2004; 57: 253–62.
29  Tarning J, Lindegardh N, Annerberg A, et al. Pitfalls in estimating 
piperaquine elimination. Antimicrob Agents Chemother 2005; 49: 
5127–28.
30  Roshammar D, Hai TN, Friberg Hietala S, Van Huong N, 
Ashton M. Pharmacokinetics of piperaquine after repeated oral 
administration of the antimalarial combination CV8 in 12 healthy 
male subjects. Eur J Clin Pharmacol 2006; 62: 335–41.
31  Watkins WM, Sibley CH, Hastings IM. The search for eﬀ ective and 
sustainable treatments for Plasmodium falciparum malaria in 
Africa: a model of the selection of resistance by antifolate drugs and 
their combinations. Am J Trop Med Hyg 2005; 72: 163–73.
32  White N. Antimalarial drug resistance and combination 
chemotherapy. Philos Trans R Soc Lond B Biol Sci 1999; 354: 739–49.
33  Baird JK, Rieckmann KH. Can primaquine therapy for vivax 
malaria be improved? Trends Parasitol 2003; 19: 115–20.
34  Clyde DF, McCarthy VC. Radical cure of Chesson strain vivax 
malaria in man by 7, not 14, days of treatment with primaquine. 
Am J Trop Med Hyg 1977; 26: 562–63. 
